Boiron France in the news

Boiron's CEO predicts China will become a top-three global market for the French homeopathic medicine manufacturer.

Boiron, the global leader in homeopathy, is diversifying its product offerings and expanding internationally while maintaining French manufacturing.

Boiron, founded in 1932 by pharmacists Jean and Henri Boiron, is the global leader in homeopathy, manufacturing 100% of its products in France, and also produces dietary supplements and cosmetics.

Boiron is ready to distribute medical cannabis in France, but administrative and political delays are preventing access for patients despite public support and successful experimentation.

Boiron is strengthening its medical cannabis strategy through a new strategic partnership with Panaxia Malta, including an option for majority acquisition starting in 2029.

Boiron partners with Panaxia Malta on medical cannabis, including an option for majority ownership, to expand its presence in the European therapeutic market.

Boiron partners with Panaxia Malta on medical cannabis distribution and may acquire majority stake from 2029.

Boiron's global revenue decreased from 2022 to 2024, reaching about "," million euros in 2024 from the manufacture and distribution of homeopathic products.

Boiron is looking to its future after a challenging year, adapting to evolving consumer health trends.

Boiron Laboratories appointed Pascal Houdayer as CEO, effective January 1, 2025, with Thierry Boiron remaining in a strategic role.

Boiron Laboratories produces homeopathic medicines from natural substances, widely used as complementary therapy in several countries including Canada and France.

Boiron experienced a decline in H1 2026 revenue and significant drops in net income and EBITDA due to lower sales volumes, increased costs, and currency effects.

France generated 217.90 million EUR in revenue for Boiron last year, representing a slight decrease from the prior period.

EW Healthcare Partners acquired a 25% stake in Boiron Group, a global leader in homeopathic and natural medicines, to support its growth and expansion, especially in the U.S.

Laboratoires Boiron has launched a line of French-made CBD cosmetics using niosome encapsulation for enhanced skin absorption.

Boiron has launched new CBD-based cosmetic products, manufactured in France using organically grown cannabis and an innovative encapsulation process.

Now is converting the former Boiron laboratory in Isneauville, which closed in late 2020, into a 1,700 m2 coworking space called 'The Office,' featuring private offices, a micro-crèche, and a restaurant, with a 2 million euro investment focusing on eco-responsibility.

Boiron is successfully recovering through strategic diversification into non-homeopathic health products and aggressive cost-cutting measures.

Boiron's 2021 revenue fell 11.4% due to insurance delisting in France, though the company offset losses through COVID tests and the acquisition of a cosmetics start-up.

Boiron reports a 16.9% revenue drop in the first nine months of 2021 due to the delisting of homeopathic medicines in France but sees growth in new product launches.